Orexigen Therapeutics

Orexigen Therapeutics is a biopharmaceutical company focuses on the development of pharmaceutical product candidates for the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is a prescription medicine that contains 2 medicines (naltrexone HCl and bupropion HCl) that may help some obese adults, or overweight adults who also have weight-related medical problems, lose weight and keep the weight off.

Company Growth (employees)
San Diego, US
Size (employees)
132 (est)+98%
Orexigen Therapeutics was founded in 2002 and is headquartered in San Diego, US

Orexigen Therapeutics Office Locations

Orexigen Therapeutics has an office in San Diego
San Diego, US (HQ)
200 3344 N Torrey Pines Ct

Orexigen Therapeutics Data and Metrics

Orexigen Therapeutics Financial Metrics

Orexigen Therapeutics's revenue was reported to be $33.7 m in FY, 2016 which is a 38% increase from the previous period.

Revenue (FY, 2016)

33.7 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

25.7 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(24.5 m)

EBIT (FY, 2016)

(57 m)

Market capitalization (21-Jul-2017)

38.9 m

Cash (31-Dec-2016)

92.5 m
Orexigen Therapeutics's current market capitalization is $38.9 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


3.4 m55.5 m24.5 m33.7 m

Revenue growth, %


Cost of goods sold

8 m

Gross profit

25.7 m

Gross profit Margin, %


R&D expense

38 m

General and administrative expense

118.6 m

Operating expense total

80.6 m86.1 m84.5 m82.7 m


(77.2 m)(30.5 m)(60.1 m)(57 m)

EBIT margin, %


Interest expense

538 k7.1 m7.4 m(7.9 m)

Interest income

65 k88 k227 k622 k

Pre tax profit

(67.3 m)(24.4 m)

Income tax expense

(1.4 m)(133 k)

Net Income

(77.7 m)(37.5 m)(68.7 m)(24.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


98.1 m104.2 m155.4 m92.5 m

Accounts Receivable

2.6 m6.8 m1.1 m


1.3 m1.5 m2.3 m23.2 m

Current Assets

178.3 m211.3 m233.9 m224.5 m


630 k857 k1.3 m1 m

Total Assets

180.1 m213 m236.6 m304.6 m

Accounts Payable

4.8 m4.2 m6.5 m15.2 m

Current Liabilities

22.9 m29.7 m32.2 m65.4 m

Additional Paid-in Capital

556.2 m574.2 m653.7 m698.2 m

Retained Earnings

(514.5 m)(552 m)(620.7 m)(645.2 m)

Total Equity

41.9 m22.3 m33.4 m57 m

Financial Leverage

4.3 x9.5 x7.1 x5.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(77.7 m)(37.5 m)(68.7 m)(24.5 m)

Depreciation and Amortization

94 k139 k223 k3.7 m

Accounts Receivable

(2.5 m)(4.3 m)5.7 m


205 k(175 k)(781 k)1.5 m

Accounts Payable

(2.3 m)2.1 m1 m11.8 m

Cash From Operating Activities

(70.8 m)6.1 m51.2 m

Purchases of PP&E

(640 k)(246 k)(538 k)(330 k)

Cash From Investing Activities

(21.3 m)(23.4 m)41.4 m(107.1 m)

Long-term Borrowings

(10 m)

Cash From Financing Activities

111.9 m2.7 m64.3 m154.6 m

Interest Paid

3.1 m3.2 m3.2 m

Income Taxes Paid

28 k1.3 m
USDY, 2016


503.1 k

Financial Leverage

5.3 x

Orexigen Therapeutics Market Value History

Orexigen Therapeutics Company Life and Culture

You may also be interested in